Ponatinib 30 MG

DRUG3 trials

Sponsors

Sebastian Bauer, Versailles Hospital, Memorial Sloan Kettering Cancer Center

Conditions

GIST, MalignantKIT Exon 13 MutationKIT Gene MutationKRAS Gene MutationLeukemia, Myeloid, AcuteNon Small Cell Lung Cancer

Phase 1

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

CompletedNCT03704688

Memorial Sloan Kettering Cancer CenterKRAS Gene Mutation, Non Small Cell Lung Cancer

Start: 2018-10-09End: 2022-02-04Updated: 2025-05-16

Phase 2

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

Sebastian BauerGIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation

Start: 2017-03-22End: 2020-09-22Target: 81Updated: 2017-05-31

Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

CompletedNCT03690115

Versailles HospitalLeukemia, Myeloid, Acute

Start: 2019-12-02End: 2024-12-31Updated: 2025-03-25

Related Papers

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Blood2023-11-021 citations

Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.

Journal of Clinical Oncology2020-05-206 citations

Abstract 1979: HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models

Cancer Research2018-07-011 citations